← Back to Search

DNA Methyltransferase Inhibitor

Decitabine for Myelodysplastic Syndrome

Phase 2
Waitlist Available
Led By Armin Rashidi, MD, PhD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is for a new treatment of relapsed AML or MDS following a stem cell transplant. Up to 4 cycles of treatment will be given, depending on how the patient responds and how well they tolerate the treatment.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Best Response
Complete Remission (CR)
Efficacy of Combined Modality Treatment (Ruxolitinib, Decitabine, and DLI) for Relapsed AML or MDS Post Allo-HCT: Rate of Overall Survival (OS)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Decitabine + Ruxolitinib + DLIExperimental Treatment3 Interventions
Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Decitabine
2004
Completed Phase 3
~1680
Ruxolitinib
2018
Completed Phase 3
~1140
Donor Lymphocyte Infusion (DLI)
2014
Completed Phase 3
~190

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
271 Previous Clinical Trials
14,611 Total Patients Enrolled
Incyte CorporationIndustry Sponsor
364 Previous Clinical Trials
55,151 Total Patients Enrolled
Armin Rashidi, MD, PhDPrincipal InvestigatorDivision of Hematology, Oncology and Transplantation, University of Minnesota
6 Previous Clinical Trials
182 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
2020. "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04055844.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top